Novo Nordisk (NVO.US) Downgrades Outlook, Triggering 20% Historic Plunge; Shareholders Initiate Class Action Lawsuit.

According to the Wise Finance app, Novo Nordisk (NVO.US) is facing shareholder litigation due to the downward revision of its full-year revenue and operating profit growth expectations. The company cited resistance in the GLP-1 market as the reason for the revision.